← Back to Search

Arm 1: ALT-803 subcutaneous only for Ovarian Cancer

Phase 2
Waitlist Available
Led By Melissa Geller, MD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of FIGO stage III or grade IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, has received at least 3 cycles of first line IV/IP cisplatin and paclitaxel chemotherapy and has stable disease or better - refer to Appendix II for FIGO staging system (Note: to be eligible for this study, the patient must receive a minimum of 3 cycles of IP therapy; however, patients may continue on IV only 1st line therapy for additional cycles as long as inclusion criteria 4.1.2 is met)
Able to begin study therapy within 3 months of final dose of first line chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 year
Awards & highlights

Study Summary

This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.

Eligible Conditions
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
ALT-803 Associated Toxicities
Incidence of Recorded Toxicity Grade 3 or Greater
Overall Survival
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2: ALT-803 intraperitoneal and subcutaneousExperimental Treatment1 Intervention
Group II: Arm 1: ALT-803 subcutaneous onlyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALT-803 Subcutaneous
2017
Completed Phase 2
~10
ALT-803 Intraperitoneal
2017
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
270 Previous Clinical Trials
14,585 Total Patients Enrolled
22 Trials studying Ovarian Cancer
551 Patients Enrolled for Ovarian Cancer
Melissa Geller, MDPrincipal InvestigatorUniversity of Minnesota
6 Previous Clinical Trials
245 Total Patients Enrolled
3 Trials studying Ovarian Cancer
119 Patients Enrolled for Ovarian Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025